AI-generated summary
The authors ran a randomized, double-blind, placebo-controlled trial in women over 50 with genitourinary syndrome of menopause. Participants received four weekly sessions of 808 nm photobiomodulation or a placebo with the device off. The authors report a significant reduction in urinary loss and better incontinence questionnaire scores in the treated group, with no significant difference in pelvic pressure or sexual function. Long-term effects were not established.
- Who or what was studied
- Postmenopausal women over 50 years of age with one or more genitourinary syndrome of menopause symptoms, including urinary incontinence
- Wavelengths
- 808 nm
- Limits stated in the abstract
- The abstract does not state the sample size and says further studies are needed to confirm long-term effects and optimize protocols.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on tandfonline.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 808 nm
- Total energy
- 4J
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Placebo-controlled, Photobiomodulation therapy, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.